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ABSTRACT 
Vaccinations are the most common painful needle procedure, with an estimated 12 billion injections 
given per year (CDC, 2019). The usual method for administration of vaccinations is through needle 
puncture, which is often painful. Children often report receiving a shot as one of the most feared and 
painful experiences (McMurtry et al., 2015). The purpose of this evidence-based practice (EBP) 
project was to improve patient experiences by decreasing the pain that is associated with vaccinations 
through the use of a nonpharmacological method for comfort via the Buzzy® device. After thorough 
analysis and synthesis of the literature, the Buzzy® device that incorporates cryotherapy and 
vibration was selected and used during vaccinations in children ages newborn to seven years of age. 
The Johns Hopkins Nursing Evidence Based Practice Model was selected as a guide for the EBP 
project development, planning, and implementation at an outpatient family practice office in 
Northern Indiana. The nursing staff performed vaccinations using standard of care for pain for four 
weeks, then the implementation of Buzzy® was used for four weeks. Data were collected using two 
pain rating scales associated with specific ages. The Face Legs Activity Cry Consolability Scale 
(FLACC) was used to observe the pain behavior of children ages newborn to two years. The Wong-
Baker FACES Pain Rating Scale was used for children ages three to seven years. Data were collected 
through electronic medical record and then analyzed through chi-square for demographic information 
and chi-square for independence for outcomes on pain. The demographic differences between the 
two groups were statistically insignificant. The FLACC outcome scores were significantly different 
between the pre- and post-intervention groups (x2(4, N=28) = 12.48, p < 0.05) while the FACES 
outcome scores were insignificant (x2(3, N=28) = 5.94, p > 0.05). The results showed that future 
research for pain management strategies during needle-based procedures is still essential for 
improving patient comfort, as well as improved patient compliance. 
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CHAPTER 1 
INTRODUCTION 
Background 
 Vaccinations are responsible for promoting human health and reducing morbidity and 
mortality from infectious diseases. However, the usual method of administration of vaccinations 
is through needle puncture, which is often painful. In children and adults, vaccinations are the 
most common painful needle procedure, with an estimated 12 billion injections given per year 
(CDC, 2019; McMurtry et al., 2015). Of course, the majority of these vaccinations occur in 
children between the ages of newborn and 18 years because of the amount of booster vaccines 
that are due in these important years of growth (CDC, 2019). The patients may consider the pain 
from these vaccinations as “mild” and others would report a much higher degree of pain and 
fear. Thus, children often report receiving a shot as one of the most feared and painful 
experiences. These concerns over vaccinations do not simply vanish over the course of 
childhood; in fact, needle apprehension is quite common in adults as well (McMurtry et al., 
2015). The most severe cases of needle fear are even diagnosed as needle phobia. Needle phobia 
is an extreme fear of medical procedures involving injections or needles. For most people, this 
fear starts to develop around the age of four or five and can last until about 10 years of age due to 
a bad immunization experience (Buzzy, 2019; McLenon & Rogers, 2018). At this point, 
individuals who are compliant with vaccination schedules will have received well over a dozen 
needle sticks. The issue results when there is a failure to implement evidence-based pain 
management strategies during these procedures. The repeated painful procedures in early 
childhood without benefit of treatment represents a high risk for the development of severe levels 
of needle fear (McMurtry et al., 2015).  
BUZZY® DEVICE FOR VACCINATIONS   
 
2 
 There are multiple psychopathological perspectives that could be applied to help 
understand the factors that lead to high levels of needle fear and phobia in children and the adults 
that they will become. Some predisposing factors may include genetic factors, life events, or 
temperament (McMurtry et al., 2015). It is thought that humans are biologically prepared to fear 
needles given fear of pain and injury. Female gender and younger age have also been shown to 
be significantly related to needle phobia. Precipitating factors refer to triggering events that have 
led to the onset of current fear. These events could be a history of fainting, significant pain, or 
severe bleeding that occur as a result of a needle procedure (McLenon & Rogers, 2018). 
Perpetuating factors are those that maintain a problem once it has become embedded and 
established in the person life. A horrible experience with a needle procedure becomes embedded 
in the person’s mind so much so, that the distressing memory of the needle related incident 
causes significant fear towards any other needle related procedure (McMurtry et al., 2015).  
 This fear of needles can lead to several negative consequences, particularly when the 
person has a moderate to high level of fear towards needle related procedures. For instance, 
children or adults that have needle fear are more likely to experience a higher amount of pain 
from the procedure (McMurtry et al., 2015). The patients are then more likely to fear health care 
professionals in general, leading to avoidance of receiving health assistance including 
vaccinations in growing children (McLenon & Rogers, 2018). People that fear needles may also 
experience a higher risk for the occurrence of fainting or seizure that can lead to serious safety 
concerns. Similarly, children that are fearful of needles may flail or run away from any needle 
procedure leading to restraint that could cause injury to the patient or the person trying to restrain 
(McMurtry et al., 2015). All of these consequences can lead to noncompliance. Thus, coming to 
the conclusion that an intervention is needed to help prevent these fears from occurring.  
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Data from the Literature Supporting Need for the Project 
 Children are exposed to several different needle-related procedures, whether it is for 
routine immunizations, intravenous insertion (IV), or venipuncture. The pain related to these 
procedures can vary from mild to severe, which can generate high levels of anxiety and fear 
(Ballard, Khadra, Adler, Trottier, & Le May, 2019). Needle phobia is estimated to affect 
approximately 10-20% of the population. While a majority of needle phobias are due to genetic 
factors and the experience of vasovagal reflexes, the remaining 30% are considered classic 
phobias arising due to traumatic experience (Susam, Friedel, Basile, Ferri & Bonetti, 2018). 
Some patients even perceive that medical personnel completed procedures without any effort to 
relieve pain or anxiety increasing the amount of risk for needle phobia (Redfern, Chen, & Sibrel, 
2017). It is recommended that whenever possible children should not be exposed to painful 
procedures. However, when unavoidable, interventions should be provided to limit the painful 
experience. Despite an increase of pain stemming from medical procedures and the distress 
associated with this, research indicates that pain management continues to be suboptimal 
(Moadad, Kozman, Shahine, Ohanian, & Kurdahi, 2016). Since this is the case, in recent years 
the interest for managing painful procedures to reduce emotional and physical effect has been on 
the rise (Canbulat, Ayban, & Inal, 2015; Inal & Kelleci, 2017).  
 Needle pain management has included several options that are both pharmacological and 
nonpharmacological, such as topical anesthetic creams, vapocoolant sprays, and distraction 
techniques. Topical anesthetic creams (5% lidocaine-prilocaine cream, 4% tetracaine gel, 4% 
lidocaine cream, and iontorphoresis) provide local anesthesia, but require a minimum application 
of 15 to 60 minutes, which is not feasible in busy outpatient office settings (Inal & Kelleci, 2017; 
Sabiner et al., 2015) They have also been associated with reports of adverse reactions (Canubulat 
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et al., 2015). Vapocoolant spray is a skin-cooling technique and contain chemicals that produce 
an instantaneous cooling effect. The coldness reduces the sensation of pain, however, there was 
no difference in pain associated specifically with vaccinations. While, these pharmacological 
inventions have some proof of being helpful in reducing pain, there were significant issues 
related to these interventions. These issues were mainly related to adverse effects, increased cost, 
excessive amount of time between placement of cream and needle procedure, and special 
training for staff (Canbulat et al., 2015; Inal & Kelleci, 2017; Canbulat Sabiner et al., 2015). 
Nonpharmcological interventions are typically divided into physical and behavioral techniques. 
Physical techniques include, but are not limited to, massages, counter-stimulations, ShotBlocker 
(numerous blunt contact points to saturate the sensory signals around an injection), stroking, and 
vibration. While some of the behavioral techniques include music distraction, cartoon distraction, 
communication, singing, reading, playing a game, video games and kaleidoscopes (Canbulat et 
al., 2015; Redfern et al., 2018; Canbulat Sabiner et al., 2015). Each of these methods is useful in 
practice and has data to support it, but there is no single integrated method to optimize pain 
relief. What is necessary to provide the most benefit for these patients is something that is easy to 
use, inexpensive, and a rapid method to relieve pain (Canbulat et al., 2015).  
 In recent years, the Buzzy® device, a vibrating motor with ice pack, combines multiple 
approaches by supplying cold analgesia, tactical stimulation, and distraction (Redfern et al., 
2018). The vibration and cryotherapy device is able to provide pain relief via the Gate Control 
Theory, meaning that prolong cold simulation blocks the pain signals, while the vibration 
distracts the patient from a painful needle procedure (Canbulat Sabiner et al., 2015). This type of 
intervention is advantageous because it is cost effective since it is easily reused through a simple 
sterilizing technique. It is also simple for a nurse to use independently (Bergomi, Scudeller, 
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Pintaldi, & Dal Molin, 2018). This device has proven effective in the pediatric population, and 
also demonstrated superior pain relief in children while confirming the feasibility of its use in a 
fast-paced care practice (Canbulat et al., 2015).  
Data from the Clinical Agency Supporting Need for the Project 
 The clinical agency where this Evidence Based Practice (EBP) project was conducted 
was a family practice office in Northern Indiana. The clinic is part of the larger organization. It is 
run by a family physician and a nurse practitioner, who provide equal amount of care to the 
patients. Within the office there are four medical assistants that assist in providing care. The 
physician, nurse practitioner, office manager, and preceptor liaison all approved of this project, 
and the family physician served as the site facilitator. This office opened in this specific location 
in January of 2019, but was previously providing care in a neighboring town. The care that is 
provided at this office ranges in complexity and age. Patient’s ages ranged from newborn to 
elderly, and the care can range from a simple vaccination to a more complex treatment for 
hypertension, diabetes, and other chronic multifaceted conditions. The practice sees 
approximately 100 patients per week, and about 20 of those patients are children. According to 
the electronic medical record technician (2019), the number of vaccinations given in the last six 
months prior to the start of the project for children, ages newborn to 18 years, was well over a 
1000. 
   With a large number of vaccinations given every year to children in the clinic, there is 
an increased need for an intervention to prevent pain. Currently, the only intervention that is used 
is comfort from the child’s parent through holding and consoling. There is also no policy or 
protocol in place for an invention during vaccinations. That being said, the clinic and agency 
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were incredibly receptive to an intervention that may help decrease the pain for children, and 
thus make their experience more tolerable.  
 The small town where this project is located is in the northern part of Indiana, close to the 
Michigan border. The total population of this town is around 1,600, with 87% of the population 
being white and 10% Hispanic or Latino (Suburban Stats, 2018). The area is not diverse, and 
thus there is a high chance of seeing more patients that are of white race. Within this populace 
there is a population of over 200 families with a least one child (under 18 years) that lives within 
the home (Suburban Stats, 2018). The median household income for people that live in this town 
is $45,500 and the average unemployment rate is 4.1%. At least 62.6% of the population has 
received at least a high school diploma and currently 17.91% of the population is enrolled in 
school. This clinic also serves more than just the local community, they also contribute to care of 
patients in neighboring towns.  
Purpose of the Evidence-Based Practice Project 
 The purpose of this EBP project was to decrease the pain associated with vaccinations in 
children. The rise of needle phobia has increased the need for an intervention to be used during 
needle-based procedures to help improve patient care and influence compliance with health care. 
A protocol for the providers in practice was developed in order to provide proper intervention for 
children who were undergoing routine vaccinations, the most common needle-based procedure in 
children. EBP projects incorporate a systematic search for evidence and critical appraisal of the 
findings with clinical expertise with patient’s and family’s values and preferences to provide the 
best practice and patient care (Schmidt & Brown, 2019) Thus, this project explored the use of an 
intervention to help relieve pain during vaccinations, and ultimately improve the child’s 
experience, and decrease fear of future needle-based procedures. In order to improve and  
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influence the child’s experience, a search for the best practice options to help intervene in the 
vaccination process was conducted. Through the research process, several options for 
intervention were found to be effective, however, the Buzzy® device, created by Pain Care Labs, 
with a combination of vibration and cryotherapy proved to be highly useful and cost-effective in 
a busy clinical practice.  
PICOT Question 
 Clinical questions are often formatted through the PICOT model. PICOT is a useful 
mnemonic device that stands for: patient population or patient condition or interest (P), 
intervention of interest (I), comparison of interest (C), outcome of interest (O), and time (T) 
(Schmidt & Brown, 2019). Using this model, a PICOT question was developed for this project. 
The PICOT question of interest is: In pediatric patients, under 7 years of age, receiving routine 
vaccinations (P), what is the effectiveness of using non-pharmacological Buzzy® device (I) 
compared to standard practice of no comfort policy (C) in helping to promote a decrease in pain 
measured by the FLACC or Wong-Baker Faces Scale (O) during an eight-week period (T)? 
Significant of the EBP Project 
 In the primary care setting, the most common pain-producing procedure in children are 
vaccinations (Redfern et al., 2018). With the rise of needle phobias and non-compliance for 
healthcare procedure, it is important for an intervention to be used in children undergoing 
vaccination. Since there is no current practice in place for comfort for pain during vaccinations at 
this clinic, it is especially important for a protocol to be in place to improve a child’s experience 
with healthcare providers. Often children are fearful of going to the doctor’s office because they 
are worried about needing a vaccination. Using an intervention to distract from the pain of 
receiving a vaccination will help improve the child’s pain and influence their feelings towards 
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healthcare providers. Ultimately, this project will seek to improve compliance, not only for child, 
but also for the adults that they will become in the future. It is important to influence children 
when they are young, when they are building their trust in individuals. This will then proceed 
into adulthood and further compliance with healthcare procedures.  
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CHAPTER 2 
EBP MODEL AND REVIEW OF LITERATURE 
Evidence-Based Practice Model 
 After thoroughly reviewing the many EBP models, the Johns Hopkins Nursing Evidence 
Based Practice Model (JHNEBPM) was selected as a guide for the EBP project development, 
planning, and implementation. This model in particular was created for the purpose of placing 
EBP into the clinical setting, thus taking what is found in literature to transform how practice is 
done (Melnyk & Fineout-Overholt, 2015). The literature found to support a change in practice 
for implementing an intervention for pain during vaccinations in children was systematically 
reviewed for best practice. A synthesis of best practice concepts was included for the 
implementation in this EBP project.  
Overview of EBP Model 
 The JHNEBPM was created in 2002 when the organizational leadership at The Johns 
Hopkins Hospital recognized a gap in the standard for nursing practice of implementing research 
results (Melnyk & Fineout-Overholt, 2015). The goal of the model that was to create a more 
useful product for bedside nurses and an easier way for evidence based practice to be embedded 
into everyday nursing care. The JHNEBPM includes core research and non-research evidence 
within the triad of professional nursing practice. The key influences behind the model are 
concepts associated with internal organizational factors like culture, environment, and staffing, 
and external factors such as accreditation, quality measures, and standards (Melnyk & Fineout-
Overholt, 2015).  
 These ideas are placed into practice through the implementation of what JHNEBPM 
refers to as the PET process. PET consists of three phases for implementation: practice questions, 
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evidence, and translation. Within these phases there are 19 steps that allow nurses to walk easily 
through the process of implementing EBP into the clinical setting (Dang & Dearholt, 2017; 
Melnyk & Fineout-Overholt, 2015). The first phase, practice question, focuses on recruitment of 
the interprofessional team to help develop the EBP question. Once the EBP question is defined 
then key stakeholders are identified, and the responsibility of the project leadership is 
established. The final stage of this phase is scheduling a team meeting to go over the next steps 
in the process. During the evidence phase, research is conducted both internally and externally. 
This evidence is then appraised on its quality and summarized for easier understanding. Once all 
the evidence has been gathered, the overall synthesis strength and quality of the evidence can 
provide the information needed to know if this practice should be implemented. This will allow 
the team to develop recommendations for change and identify the need for change in practice. 
The final phase is translating this evidence into practice. This process takes several steps due to 
the process of identifying the right location, feasibility of the change, and appropriateness of 
recommendations. Once this has been recognized the project leader can start creating an action 
plan and secure the support needed to carry out the action plan. The next logical step is to 
implement the action plan and evaluate the outcomes. These outcomes are reported to those 
involved in the action plan, and next steps are identified if needed. Finally, if the change in 
practice was seen as significant, then the modification can be fully implemented into everyday 
practice (Dang & Dearholt, 2017).  
Application of EBP Model to DNP Project 
 The JHNEBPM is useful for application in project planning, implementation, and 
translation into practice. Using the 19-step process and three phases, this model was used for 
implementation of the Buzzy® device during vaccinations in pediatric patients. In the first phase, 
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the key stakeholders were identified, and a discussion on the use of the Buzzy® device was 
addressed. The key stakeholders involved include a physician, nurse practitioner, several medical 
assistances, and the participants plus their families. The evidence surrounding the use of Buzzy® 
was discussed with the key stakeholders, which was identified as being useful for practice in the 
pediatric population that is seen at this family practice office. Since, the change is necessary for 
the practice, use of the Buzzy® device will be implemented into practice.  
Strengths and Limitations of EBP Model for DNP Project 
 There are significant strengths that are associated with the use of the JHNEBPM for this 
DNP project. This EBP model was specifically created and designed for nurses, by helping them 
easily translate evidence into practice. This is one of the largest strengthens for any DNP project 
because it creates an easy format for nurses and advanced practice nurses to use. The model is 
also useful by integrating practice, research, and education, all of which are necessary when 
creating and implementing a change into practice. Additionally, this model can be used in both 
inpatient and outpatient settings. This model was initially designed with bedside nursing in mind, 
but it is also easily translated into the outpatient setting. As Melnyk and Fineout-Overholt (2015) 
state, “The JHNEBPM Model applies to clinical, learning, and operational question in any 
setting where nursing is practiced, and in academic setting at schools of nursing at the 
undergraduate and graduate level” (p. 416). These areas are all important strengths for DNP 
project planning and implementation, however, one of the key areas that separates the 
JHNEBPM from other EBP model is the fact that it relies on an open system. Through the PET 
process, the best practices to answer practice questions are identified, which leads to 
improvement in all areas of practice including clinical, learning, ad operations. However, at any 
point throughout the model, new ideas and questions may arise, thus triggering a new EBP cycle. 
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Since this model is an open system, it can be influenced by several different factors like the 
culture of the practice, the patients that are seen in the practice, and standards/quality measures. 
This makes the model dynamic and allows for openness to all areas that make affect the EBP 
project process. This makes it easier for the key stakeholders and project manager to identify 
potential threats to the EBP project (Melnyk & Fineout-Overholt, 2015). 
 However, every model is not without its weaknesses. As previously mentioned, this 
model is rather complex and detailed. This includes the complexity of the openness aspect of the 
model. With every EBP project there are multiple factors that are influencing the project itself, 
while identifying these areas can be helpful it can also be time consuming and cause the project 
to change altogether (Melnyk & Fineout-Overholt, 2015). Likewise, the 19-step process can be 
rather burdensome compared to other models that are more succinct in their steps. For this 
reason, the JHNEBPM is more useful in an individual office setting rather than at the 
organizational level (Newhouse, Dearholt, Poe, Pugh, & White, 2004).  
Literature Search 
Sources Examined for Relevant Evidence  
 The research for this project started in Cochrane and Joanna Briggs Institute (JBI), as 
they often provide high quality evidence to support practice. The search began with Cochrane, 
using the same limiters throughout which included: the year limiter of 2014 to 2019 and the 
English language. However, different key terms were used to help produce the most evidence. 
The first search included the key terms: “Buzzy” AND pain* AND vaccin* OR immuniz*. Of 
these results, two of the articles were relevant to my topic. From this search, the decision was 
made broaden the search terms by using needle instead of focusing specifically on vaccinations.  
Thus, the search terms for Cochrane became, “Buzzy” AND pain* AND needle. This resulted in 
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nine trials, of which, four were relevant for the project, however one was a duplicate from the 
previous search. While still searching in Cochrane, the term “Buzzy” was changed to be included 
in all text instead of the standard title abstract keyword. The search was then “Buzzy” AND 
pain*, creating an even broader range for article obtainment. This resulted in one systematic 
review, that was not relevant due to lack of use of the Buzzy® device in the review, and 25 trials. 
Based on the trials, there were ten that were significant for the project, with three of the ten being 
duplicated from previous searches. A final search was completed in Cochrane as several mesh 
terms that could have resulted in further evidence. The key terms used for the final search were: 
Vibrat* AND pain* AND cryotherapy, resulting in nine trials. Four of the trials were duplicates 
from previous searches and two were new that were helpful for the project. In total, 13 trials 
were significant for the project. After reviewing these articles, they were then narrowed down to 
include only those that identified pediatric patients (0-18 years old) undergoing a needle-based 
procedure (IV, blood specimen collection, or vaccination/IM injection) utilizing only Buzzy® 
(not in combination with other interventions) against a control group (standard of practice) and 
identified pain as a major outcome being measured. The setting of the research project did not 
matter because this would have drastically limited the amount of useful evidence. Additionally, 
one of the articles focused specifically on cognitively delayed children, while significant, it was a 
very specific group of children. Based off of these inclusion/exclusion criteria, six relevant 
articles were selected.  
 Following the Cochrane database search, JBI was then assessed for quality systematic 
reviews or any relevant evidence. Again, using the same limiters throughout each search, which 
included only limiting the date range between 2014 to 2019. JBI was searched using the key 
terms, “Buzzy” AND Pain* OR discomfort, which provided four results that included 
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recommended practices and evidence summaries, but no systematic reviews. Then completing a 
more detailed search that included the key terms of “Buzzy” OR vibrat* AND inject* OR 
needle* AND pain* OR discomfort. The results included 11 different recommended practice, 
systematic review protocols, and evidence summaries. Using one of the recommended protocols 
for citation chasing, one article was found to be relevant and it was also one that had been found 
in Cochrane. Likewise, one of the systematic review protocols also provided relevant articles 
through citation chasing, but the articles were the same ones found in Cochrane, thus providing 
no new evidence.  
  Without much success in JBI, the search continued in CINAHL. In all of the searches 
conducted in CINAHL the limiters of date range between 2014 to 2019, Scholarly Journals, and 
English language were included. The first search terms included: “Buzzy” OR “cooling vibrat*” 
AND pain* OR discomfort, which resulted in 15 different articles. Of the 15 articles, one 
systematic review was found to be relevant and 11 other articles were also significant. In total 12 
articles were significant, however seven of the articles were also found in Cochrane. Following 
this search, the key terms were simplified to include, “Buzzy” OR “cooling vibrat*” AND 
needle. This recorded seven results, four that were relevant, but not new from the previous 
search. The final, search included vibrat* AND cool* AND pain. There were nine results from 
these terms, but only one was relevant and it was also found in previous searches. In total, after 
taking out duplicate results, only the systematic review was left as an additional reference.  
 The last three databases that were searched included Medline, Nursing & Allied Health 
(ProQuest), and Health Source.  In all three databases, very simple key terms were used that 
included “Buzzy” AND pain*. The limiters that were included were date ranges between 2014 
and 2019 English language, peer review, full-text, and scholarly journals. In Medline, there were 
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27 results. Of those 27 results, 13 were relevant to the project, but they were all articles that were 
duplicates of ones found in Cochrane and CINAHL. In Nursing & Allied Health, there were 25 
results. Of those 25, only one was based on inclusion and exclusion criteria listed previously, and 
it too had been found in a previous search in Cochrane and CINAHL. Likewise, Health Source 
produced five results, with one that was relevant and also found in both CINAHL and Cochrane. 
The search was then conducted using the key terms, “Buzzy” AND pain AND vaccin* OR 
immun*. In Medline, this resulted in three clinical trials, one was not relevant due to the 
participants being adults and the other two articles were previously found in CINAHL and 
Cochrane. Nursing & Allied Health had five results, all of which were not used for this project 
due to the lack of inclusion and exclusion criteria. Health Source contained no results using the 
key words listed.  
 Once most of the articles were found, then reviewing of the citations in the systematic 
review to find out if there were other articles that should be included in my final literature 
review. Several of the articles that were used as evidence in the systematic review were also 
found while searching the databases, however, there were two articles that were searched for 
further significance. Only one of the articles was within the inclusion criteria of pediatric patients 
undergoing a needle-based procedure using Buzzy® to improve pain, however, it included the 
use of Buzzy® in combination with other interventions. Thus, both articles were not selected for 
final review due to lack of agreement with the inclusion and exclusion criteria.   
 For the final search, to prove that saturation had been reached and exhausted all efforts, a 
hand search was completed for evidence found on Buzzy®’s website. On the website, it includes 
a section on different research articles that have used Buzzy® for pain relief. Thus far, almost all 
the articles that were selected were included on the Buzzy® website. However, there were two 
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articles that were reviewed more closely. These articles ended up not being included in the final 
review because of exclusion criteria (Table 2.1).  
Levels of Evidence 
 The source that was selected for use in leveling the evidence was the Johns Hopkins 
Nursing Evidence-Based Practice Research Appraisal tool. This leveling tool provides both 
appraisal for the level of evidence and the quality of the evidence. When appraising the level of 
evidence, there are three simple questions for both appraisal of randomized control trials and 
systematic reviews. If the answer is “yes” to all three questions then the level of evidence is a 
level 1 (highest level of evidence), however, if there are any that are “no,” that lowers the level 
of evidence based on how many answers were “no.” 
 While reviewing the selected articles for the final literature review, they were all level 1 
evidence. The systematic review that was used checked all the boxes for being included in the 
level 1, as well as all seven of the randomized control trials were also level 1 evidence. Thus, 
making the articles all high evidence in the ranking according to the tool used.  
Appraisal of Relevant Evidence 
 The benefit of using the Johns Hopkins Nursing Evidence-Based Practice Research 
Evidence Appraisal tool allows for quality appraisal as well. It is a simple appraisal tool that 
allows the user to answer 12-15 simple questions about each article (depending on if it is a RCT 
or systematic review). The user walks step-by-step through an article to make sure all the 
important information is present to make for a quality study and article. Then once all the “yes” 
or “no” questions have been answered, it is up to the user to identify if all the areas are being met  
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Table 2.1 
Evidence Search Table 
Database Yielded Duplicates Reviewed Accepted 
Cochrane 68 8 13 6 
JBI 32 0 1 0 
CINAHL 31 11 12 1  
Medline 30 13 13 0 
ProQuest 30 1 1 0 
Health Source 5 1 1 0 
Citation Chasing 5 0 4 0 
Total 201 34 45 7 
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to make the evidence high quality, or if there are areas of weakness making the quality either 
good or low/major flaws. If the quality is high then the articles are consistent with generalizable  
results, have a sufficient sample size, designate a specific control group, define conclusions, and 
use consistent recommendations for future practice that are based upon evidence.  
 While closely reviewing all seven articles selected for use to support the evidence for 
practice change, the articles that were found only ranked as high or good quality. Any articles 
that were of low quality were dismissed from use in the final literature review. Overall all of the 
articles that were selected for final review were considered level 1 evidence with either high or 
good quality.  
 Level 1 evidence. Ballard et al. (2019), recently published a systematic review and meta-
analysis discussing the use of the Buzzy® device for pain management in children undergoing 
needle-related procedures. The search method conducted for this systematic review included 
searches in PubMed, Ovid MEDLINE, Ovid All EBM Reviews, Ovid Embase and Ovid 
PsychINFO, and CINHAL between the dates of inception until December 18, 2017. The 
database searches were completed with the assistance of a librarian with special training and 
skills in literature searches. The authors had strict inclusion and exclusion criteria that included 
only randomized control trials which compared the Buzzy® device to a control group of infants, 
toddlers, children, and adolescents from 28 days to 18 years old who required a needle-related 
procedure, such as immunization, venipuncture, IV insertions, intramuscular or subcutaneous 
injections. The studies that were included must also use a combination of both vibration and 
cooling therapy, not individually. Finally, there was not a language restriction set in place during 
the search. Based on this inclusion and exclusion criteria, a total of nine randomized control 
trials were included in the systematic review and seven were included in the meta-analysis.  
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 In total, 1,145 children and adolescents (age range between 3 to 18) were included 
between 2011 and 2018. The studies had a range of control groups that were used to compare 
with the Buzzy® device. These groups either had an absent nonpharmacological intervention/no 
intervention control group, vapocoolant spray and/or topical anesthetic, and distraction cards. 
The needle procedures also varied across studies, three included IV insertions, two included 
venipunctures, two others included both IV and venipuncture, and the last two included 
immunizations. The primary outcome measured was needle-related procedural pain intensity that 
was evaluated during or immediately after the procedure by at least one pain scale, which 
included self-reported by the visual analog scale, numerical rating scale, verbal rating scale, or 
faces scale; parent-reported or observer-reported through two different scales including the 
Children’s Hospital of Eastern Ontario Pain Scales or the Faces Legs Activity Cry 
Consosolability Scale (FLACC). The results of these studies showed that the Buzzy® device 
demonstrated a statistically significant effect on reducing both self-reported pain and parent-
reported and/or observer-reported pain during needle-based procedures. Through critically 
appraising this study, it was placed as a level 1 and high quality based on the JHNEBP tool.  
 Bergomi, Scudeller, Pintaldi, and Dal Molin (2018), conducted a randomized control trial 
for the purpose of evaluating non-pharmacological techniques, vibration combined with 
cryotherapeutic topical analgesia by the use of the Buzzy® device and animated cartoons, in 
relations to pain and anxiety relief during venipuncture in children. The study focused on 
children between the ages of five and 12 years old. The child and their parents received thorough 
instruction for the potential use of a non-pharmacological intervention during venipuncture. The 
final consented participants included 150 children undergoing venipuncture. The participants 
were randomly split into any of the four groups: no intervention, animated cartoon distraction 
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alone, animated cartoon with Buzzy® device, and Buzzy® device alone. The randomization 
occurred through the use of an independent statistician using the Strata 13. This was immediately 
followed by the preparation of numbered opaque sealed envelopes, which included the allocated 
groups. The envelopes were then divided into the appropriate locations and to the appropriate 
participants. The pain and anxiety scale were then explained to the participants, with the primary 
measurement being focused on pain. The pain scale used to evaluate the intensity of pain was the 
Wong-Baker Faces Pain rating scale. The secondary outcome were the nurses’ and parents’ 
perception of the child’s pain. The comparison of continuous variables between all four of the 
groups were statistically analyzed by the way of one-way analysis of variance. Comparison of 
the categorical variables was performed by way of the Pearson’s c2 test. A p-value of <0.05 was 
considered to be statistically significant. The data were run through the Strata computer software. 
Overall, the results concluded that children’s perception of pain was less in the non-
pharmacological intervention groups compared with no intervention. Buzzy® was highly 
effective in children that were younger than nine years of age (p = 0.04). Additionally, there was 
also a significant efficacy among the Buzzy® and cartoon group (p = 0.04) for the nurse’s 
perception of child’s pain and in the Buzzy® group alone for the mother’s perception of the 
child’s pain (p = 0.002). Overall, the study proved to be a level 1 with good quality based on 
analysis using the JHNEBP tool. 
 Canbulat Sahiner, Ayban, and Inal (2015), conducted a randomized control trial that was 
conducted for the purpose of investigating the effect of external cold and vibration stimulation 
via the Buzzy® device on pain and anxiety levels in children that were undergoing peripheral 
intravenous cannulation. The sample for inclusion criteria included patients that were aged 7 to 
12 years who were having IV cannulation performed. Participants were excluded if they had a 
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break in the skin where the device was to be placed, critically ill or had nerve damage, 
neurodevelopmental delay, verbal difficulties, use of analgesic within the last six hours, or 
history of syncope due to blood specimen or immunization. Based on this criteria and parental 
consent, 176 children were randomly assigned to the non-intervention group or the cold and 
vibration therapy group. Immediately after the IV cannulation procedure, the child’s pain level 
was assessed through self-report via the Wong-Baker Faces Scale and the visual analog scale. 
The data were analyzed with the SPSS version 15.00, which resulted in a significant p value of 
<.05. The pain and anxiety levels of the children were compared with t test and demographic 
information was compared with frequency and c2. The results of the study proved to be 
significant in the external cold and vibration stimulation group, lower pain levels were recorded 
for both self-reported scales compared to the non-intervention group (p < .001). Based on the 
information reported in this article and through thorough analysis using the JHNEBP tool, the 
article is considered a level 1 with good quality.  
 Canbulat, Inal, and Akbay (2015), reported a study that investigated the effect of 
combined stimulation of skin with external cold and vibration via the Buzzy® device measuring 
the pain and anxiety levels during immunization in children. This study was a randomized 
control trial conducted during routine school immunizations in children that were all seven years 
old receiving the same required DTaP vaccination via intramuscular injection. Those that were 
not include in the study were participants that had break in the skin where the device was to be 
used, nerve damage in the affected extremity, critically ill or unstable, neurodevelopmental or 
verbal difficulties, or history of syncopal episodes with blood specimen or immunizations. The 
104 children that had parental consent were randomized based on a computer-generated table or 
random numbers into two equal groups. Children that were in the control group did not receive 
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an intervention whereas those in the invention group received external cold and vibration 
stimulation via the Buzzy® device. The level of pain was assessed in each child using the Wong-
Baker FACES pain rating scale and verbal reports. The data were then analyzed using the SPSS 
software 15.00. The p value less than 0.05 was considered significant in this study. The 
comparison between the pain levels was analyzed using t test, while the demographic data were 
compared using frequency and chi-square tests. The results showed that self-reported procedural 
pain levels were significant between the study groups (p = .001). The experimental group had 
significantly lower pain levels (p = .001) than the control group. Based on the JHNEBP tool, the 
study was considered a level 1 with good quality based on lack of details included in the study 
design.  
 Inal and Kelleci (2014), completed a randomized control trial investigation into the effect 
of external cold and vibration stimulation via Buzzy® on pain and anxiety levels of children 
during blood specimen collection. The inclusion criteria for this study included children between 
the ages of 6 and 12 years who required blood tests. The participants were excluded if there was 
a break in the skin where the device was to be placed; if they had nerve damage in the affect 
extremity; if they were chronically ill or unstable, neurodevelopmental delay, verbal difficulty; if 
they had some sort of analgesic within the last six hours; or have a severe history of syncopal 
episodes during needle-based procedures. For participants and parents that consented to the 
study, demographic information was collected and thorough instructions on the device and pain 
scales were administered. Those that consented included 120 children, and they were randomized 
on the basis of a computer-generated table of random numbers into two equal groups. The 
control group did not undergo any intervention, however the experimental group received the 
application of cold and vibration stimulation via Buzzy®. After the procedure, pain levels were 
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assessed by self-reports, parents’ and the observer’s report. The pain scale that was used for 
reporting was the 0-10 Faces Pain Scale-Revised (FPS-R). The pain scale has been used in over 
140 studies and is accepted as a well-established measuring tool. The data were then analyzed 
with SPSS version 15.0; a p < 0.05 was considered to be significant. The data were compared 
using t-test for pain and chi-squared and frequency for demographic information. The external 
cold and vibration stimulation group had significantly lower pain levels in the self-reported, 
parent reported, and observer reported pain levels compared to the control group (p < .001). The 
details included in this study were consistent with an analysis of level 1 and high-quality rating 
per JHNEBP tool.  
 Moadad, Kozman, Shahine, Ohanian, and Badr (2016), completed a randomized control 
trial that explored the used of external cold and vibration via the Buzzy® device and its effect on 
pain ratings in children, their parents, and nurses during peripheral IV insertion. The participants 
that were selected to be included were 4 to 12-year-old children. The exclusion criteria included 
those with a break in the skin where the device is to be placed; if they are critically ill or 
unstable; history of taking an analgesic in the last four hours; history of a syncopal episode 
during blood draws; and history of neurodevelopmental delay or verbal difficulties. Based on 
these inclusion and exclusion criteria, there was a total of 48 that were analyzed. The children 
were randomized into a control group and intervention Buzzy® group. Randomization occurred 
by flipping a coin (heads = control; tails = intervention). Pain was measured using the Wong-
Baker FACES Pain Rating Scale. Pain was reported by the child, their parents, and the nursing 
staff. All three were blinded to each other’s pain rating score, as to decrease the bias on the 
score. The statistical data were analyzed using the SPSS for Windows version 22. The 
demographic information was described using frequency and means/standard deviations. The 
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pain scores were compared using ANOVA. The authors of this study also looked closely at 
separate age groups by using univariate analysis and dividing the ages into two groups; 4 to 7 
years and 8 to 12 years. The results of study concluded that children in the control group reported 
higher scores on the Wong-Baker FACES Scale than those that were in the intervention group (F 
(2/45 = 7.07, p = 0.011), nurses also rated children's pain higher when the Buzzy® device was 
not applied (F (2/45 = 6.7, p = 0.014). When comparing ages, the results showed that younger 
children had significantly higher pain scores in the control group versus those in the Buzzy® 
intervention group (F (2/19) = 8.96, p = 0.007). However, pain ratings by mothers were not 
significantly different between groups. Overall, the Buzzy® intervention group was significant 
when patient-reported pain and nurse-reported pain was involved, making the device still useable 
and helpful in practice. The authors of this study concluded that Buzzy® may be most beneficial 
in younger children because this age group is more easily distracted and would not focus on the 
needle as much as older children. Through thorough analysis using the JHNEBP tool, this study 
would be a level 1 with high quality evidence.  
 Redfern, Chen, and Sibrel (2018), completed a randomized control trial for the purpose of 
measuring the impact of combining cold and vibration on pain scores during routine vaccination 
in children. The children involved in this study were between the ages of 3 and 18 years of age 
and undergoing a routine vaccination at their annual well visit. The participants were excluded if 
they had used Buzzy® before; if they had a history of Reynaud’s syndrome or sickle cell disease 
with extreme sensitivity to the cold; there was a break in the skin where the device was to be 
used; nerve damage present in the affected extremity; history of neurodevelopmental delay or 
verbal difficulties; or analgesia used within the past six hours. The number of injections that the 
participant was to receive did not excluded them from the study. Verbal and formal consents 
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were filled out for those that agreed to participate per the patient and the legal guardian. There 
were 51 children undergoing vaccinations that consented to participate in the study, 26 were 
randomized to the Buzzy® group and 25 to the control group. Randomization was completed by 
way of a randomization schedule created by the research staff using www.randomizer.org prior 
to the beginning. Folded paper tags with group assignments were placed into sequentially 
numbered, sealed envelopes and opened at the time of consent. An explanation of the device was 
given during the consent process, the authors felt that child’s expectation and perception of the 
pain may have bias due to knowing how the device works so they required participants to rate 
how much they thought the injection would hurt prior to the procedure. However, the study still 
measured pain following the procedure by way of self-reported, parent-reported, and observer-
reported. All of the assessments of pain used the Wong-Baker Faces Pain scale. The data 
collected were analyzed using the SAS version 9.2. Chi-squared and t-tests were used to 
investigate the categorical and continuous variables. The associations between parent, child, and 
observer ratings, as well as the association of pain ratings with satisfaction ratings were analyzed 
using Pearson correlation coefficient. Significance level was set at p < 0.05. When comparing the 
post-procedural pain ratings given by children, those that were in the Buzzy® group reported 
significantly lower pain than those in the control group (mean difference of –2.39; 95% CI –0.48 
to –4.24; t = --2.53; p = 0.015). The mean pain reported between those receiving one injection 
and those receiving more than one was not statistically different (p = 0.36). When comparing 
ratings of post-procedural pain for the observers and parents, the observers rated pain lower (p = 
0.04), while the parents were not significant compared to the control (p = 0.09). The details of 
this study were significant and through analysis using the JHNEBP tool it was found to be a level 
1 with high quality evidence (Table 2.2) 
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Table 2.2 
 
Evidence Summary Table 
Author(s) Purpose Design/Quality 
Rating 
Sample Measurement/Outcome Results 
Ballard, A., 
Khadra, C., Adler, 
S., Trottier, E. D., 
& Le May, S. 
(2019). 
 
The purpose of this 
study was to 
systematically 
review the use of 
Buzzy® in several 
needle-related 
procedures and 
how it affected 
pain and anxiety.  
Systematic Review 
• Level 1 
• High 
Quality 
Randomized 
control trials 
comparing 
Buzzy® device to 
control in infants, 
toddlers, children, 
and adolescents 
from 28 days to 18 
years old who 
required a needle-
related procedure. 
A total of 1145 
children were 
involved in this 
systematic review. 
 
 
9 RCT were used in the 
systematic review; 7 
RCT were used in the 
meta-analysis. They 
measured pain during 
needle based procedures 
using a range of 
different pain rating 
scales.  
 
Buzzy® device on 
self-reported pain, 
the overall effect 
was found to be 
significant (SMD 
–1.12; 95% CI: -
1.53 to -0.71; P 
<0.0001).  
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Bergomi, P., 
Scudeller, L., 
Pintaldi, S., & Dal 
Molin, A. (2018). 
The purpose of this 
study was to 
evaluate vibration 
combined with 
cryotherapeutic 
topical analgesia 
using Buzzy® 
devices and 
animated cartoon 
on pain and 
anxiety during 
venipuncture. 
Randomized 
Control Trial 
• Level 1 
• Good 
Quality 
 
 
Children between 
the ages of 5 and 
12 years were 
included. This 
study included 150 
children.  
The study measured 
animated cartoon 
distraction alone, 
animated cartoon with 
Buzzy® device, and 
Buzzy® device alone.  
The child’s perception 
of pain was evaluated 
using the Wong-Baker 
Faces Pain rating scale.  
 
The secondary 
analysis showed 
that Buzzy® was 
highly effective in 
children younger 
than 9 (p = 0.04). 
Also, a significant 
efficacy was 
recorded in the 
Buzzy® and 
Cartoon group (p 
= 0.04) for the 
nurse's perception 
of the child's pain, 
and in the Buzzy® 
group for the 
mother's 
perception of the 
child's pain (p = 
0.002).  
Canbulat Sahiner, 
N., Ayhan, F., & 
Inal, S. (2015). 
 
The aim of this 
study was to 
investigate the 
effect of external 
cold and vibration 
stimulation via 
Buzzy® on the 
pain and anxiety 
level of children 
during peripheral 
Randomized 
Control Trial 
• Level 1 
• Good 
Quality 
The sample 
consisted of 176 
children ages 7 to 
12 years who 
were randomly 
assigned to two 
groups: a control 
group that 
received no 
peripheral IV 
cannulation 
intervention and 
The children’s pain 
levels immediately after 
the peripheral IV 
cannulation procedure 
were also assessed via 
self-reports using the 
Wong Baker Faces Scale 
(WBFC) and the visual 
analog scale (VAS)  
 
The children in the 
external cold and 
vibration 
stimulation group 
had significantly 
lower pain levels 
than the control 
group according to 
their self- reports 
(both WBFC and 
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intravenous (IV) 
cannulation  
 
an experimental 
group that 
received external 
cold and 
vibration via 
Buzzy®  
VAS scores; p < 
.001).  
 
Canbulat, N., İnal, 
S., & Akbay, A. 
(2015). 
This study 
investigated the 
effect of the 
combined 
stimulation of skin 
with external cold 
and vibration via 
Buzzy® on the 
pain and anxiety 
levels in children 
during 
immunization.  
 
Randomized 
Control Trial 
• Level 1 
• Good 
Quality 
Inclusion criteria 
were 7-year-old 
children who 
required 
immunization 
(DTaP). The 
study included 
104 participants.  
 
The pain and anxiety 
levels of the children 
were assessed using the 
Wong-Baker FACES 
scale and Children Fear 
Scale.  
 
The self- reported 
procedural pain 
levels showed 
significant 
differences 
between the study 
groups (P 5 .001); 
the experimental 
group (1.38 6 
1.92) had 
significantly lower 
pain levels (P 5 
.001) than the 
control group 
(3.42 6 3.10).  
Also, the 
experimental 
group’s pain 
levels based on the 
two observers’ re- 
ports (1.31 6 1.36 
and 1.15 6 1.27) 
were significantly 
lower than that of 
the control group 
(4.85 6 2.72 and 
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4.60 6 2.94) (P 5 
.001 for both).  
Inal, S. & Kelleci, 
M. (2014).  
To investigate the 
effect of external 
cold and vibration 
stimulation via 
Buzzy®® on pain 
and anxiety levels 
of children during 
blood specimen 
collection.  
 
Randomized 
Control Trial 
• Level 1 
• High 
Quality 
The sample 
consistedof 120 
children aged 
from 6 to 12 
years undergoing 
phlebotomy  
 
Immediately after the 
blood specimen 
collection procedure, the 
children’s pain levels 
were assessed via self- 
report, the parents’ and 
the observers’ reports 
using Faces Pain Scale-
Revised (FPS-R). 
Children in the 
external cold and 
vibration 
stimulation group 
had significantly 
lower pain levels 
by self-report, 
parent report, and 
observer report 
than the control 
group (p<.001).   
Moadad, N., 
Kozman, K., 
Shahine, R., 
Ohanian, S., & 
Badr, L. K. 
(2016). 
 
To investigate the 
effects of external 
cold and vibration 
via the 
“BUZZY®” on 
pain ratings of 
children, their 
parents and nurses 
during peripheral 
IV insertion, to 
measure the time 
to a successful IV 
insertion and to 
assess the factors 
that are associated 
with pain 
perception of 
children.  
Randomized 
Control Trial 
• Level 1 
• High 
Quality 
The participants 
included 4-to 12-
year-old children 
who required an 
IV insertion at 
either the 
pediatric unit of 
the AUBMC or 
the Children's 
Cancer Center of 
Lebanon. 
Included 48 
children in the 
study.  
 
The dependent variable 
was pain as assessed on 
the Wong-Baker FACES 
Pain Rating Scale.  
 
The results 
indicated that 
children reported 
higher scores on 
the WBFPS when 
they did not have 
the “BUZZY®” 
applied, F (2/45 = 
7.07, p = 0.011, 
nurses also rated 
children's pain 
higher when the 
“BUZZY®” was 
not applied, F 
(2/45 = 6.7, p = 
0.014.  
Younger children 
had significantly 
higher pain scores 
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 in the “No 
BUZZY®” group 
compared to the 
“BUZZY®” 
group, F (2/19) = 
8.96, p = 0.007  
Redfern, R. E., 
Chen, J. T., & 
Sibrel, S. (2018). 
The purpose of this 
study was to 
measure the impact 
of combing cold 
and vibration on 
pain scores during 
routine 
vaccination. 
 
Randomized 
Control Trial 
• Level 1 
• High 
Quality 
 
Children who were 
at least 3 to 18 
years old were 
eligible present for 
well-child with 
immunization and 
Buzzy® naïve. 
This study 
included 50 
children.  
Pain and anxiety were 
measured by the child 
using the Wong Baker 
Faces Pain Scale during 
immunizations.  
In comparing the 
post-procedure 
pain ratings given 
by children, those 
in the Buzzy® 
group reported 
significantly lower 
pain than those in 
the control group, 
with a mean 
difference of 
−2.39 (95% CI 
−0.48 to −4.24, t = 
−2.53, p = 0.015).  
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Synthesis of Critically Appraised Literature 
 Buzzy® (cryotherapy and vibration).  
 The use of pharmacological and nonpharmacological treatment for pain and anxiety 
during needle-based procedures has become increasingly important over the past several years 
since the rise of needle-related phobias in the pediatric population. Some of the most significant 
treatments have been the use of topical anesthetic creams, vapocoolant sprays, and distraction 
techniques (cartoons, blowing up a balloon, blowing bubbles, etc) (Ballard et al., 2019; Bergomi 
et al., 2018; Canbulat et al., 2015; Redfern et al., 2018). However, more recently, there has been 
an indication for a combination treatment option that has proven equally as significant. The 
combination treatment that has become increasing popular across the nation is a device called 
Buzzy®. It is a combination of vibration and cold therapy (cryotherapy) that comes in a bee 
shaped design (Ballard et al., 2019; Canbulat et al., 2015; Moadad et al., 2016; Redfern et al., 
2018). The bee shaped device combines the cooling ice pack wings and vibrating motor body. 
The way that this device works is through The Gate Control Theory. This theory suggests that 
pain is transmitted from the peripheral nervous system to the central nervous system, where it is 
modulated by a gating system in the dorsal horn of the spinal cord (Ballard et al., 2019; Canbulat 
et al., 2015; Moadad et al., 2016; Redfern et al., 2018). The afferent pain-receptive nerves, that is 
the A-delta fibers and slower C fibers carrying pain messages, are blocked by faster non-noxious 
motion nerves. The prolonged cold and vibration stimulates the C fibers and may block the A-
delta pain signals. The addition of cold treatment may also result in enhanced activation of 
supraspinal mechanism, raising the body’s overall pain threshold (Ballard et al., 2019; Canbulat 
et al., 2015; Moadad et al., 2016; Redfern et al., 2018). 
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 While Buzzy® works great for the treatment of pain perception during needle-based 
procedures, it is also cheap and effective almost immediately. One of the biggest disadvantages 
to using a topical anesthetic or vapocoolant spray is that they can take up to 45 minutes for full 
effect and they can also be quite costly (Canbulat Sahiner et al., 2015). However, Buzzy® works 
almost instantly. The reusable ice pack wings are frozen solid prior to patient use and once they 
are pulled out of the freezer, they are connected to the battery operated vibrating bee body. The 
bee is then placed on the patient’s needle site for 30 seconds, and then moved 3 to 5 cm proximal 
to the site immediately prior to the needle stick (Canbulat Sahiner et al., 2015; Moadad et al., 
2016). In total, this device takes far less time, making it ideal for busy clinics and emergency 
departments. Additionally, since the device is easily cleaned off between patients for reuse it also 
saves money compared to other products that are not reusable (Ballard et al., 2019; Inal & 
Kelleci, 2014). 
 Pain. 
 As previously stated, the largest reasoning for the use of Buzzy® is to limit pain and 
anxiety. Pain is always the primary outcome of measurement when dealing with a patient 
undergoing a needle-based procedure. More often this is based on the fact that pain is much 
easier to measure than anxiety. However, it can still be difficult to measure pain in children due 
to subjectivity, as well as the understanding of the child (Ballard et al., 2019). There are several 
different scales that are used to measure pain and anxiety, as well as different scales for different 
age ranges. Since Buzzy® is used most commonly in pediatric care, the most frequently used 
pain scale is the Wong Baker Faces Scale (Ballard et al., 2019; Bergomi et al., 2018; Canbulat et 
al., 2015; Canbulat Sahiner et al., 2015; Inal & Kelleci, 2014; Moadad et al., 2016; Redfern et 
al., 2018). This scale consists of six cartoon faces that range from neutral expression (0 = very 
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happy/no pain) to a screaming face (10 = worst pain imaginable). This scale is most useful for 
children that are at least three years to around seven years of age because at this age range they 
can understand cartoon faces and emotions, but they are not fully able to understand their pain on 
a scale from 0 to 10. Another commonly used pain scale is the Visual Analog Scale. This scale 
tries to measure a characteristic or attitude that is believed to range across a continuum of values 
and cannot be easily measured directly (Canbulat et al., 2015). That means this scale is usually a 
horizontal line, 100 mm in length, with two-word descriptors at each end. One end will say “no 
hurt” and the other end with say “worst hurt”. The child will then make a mark on the line at the 
point where he or she feels represents his or her perception of pain. Then the point of pain is 
determined by measuring where this mark lies in accordance with the left-end of the line (Ballard 
et al. 2019; Canbulat et al., 2015). The last commonly used pain scale for children that can be 
used during needle-based procedures is the Face Legs Activity Cry Consolability Scale 
(FLACC). The FLACC scale can be used on children between the ages of two months and seven 
years, however, it is not commonly used in children after the age of three unless they are non-
verbal or sedated (Ballard et al., 2019). Each of the five categories in this scale are assessed and 
scored from 0-2, 0 being the child shows no particular expression, relaxed, quiet, and not crying, 
or 2 being the child is crying, restless, screaming, and not consolable. The scores are then added 
up to get the overall pain rating between 0 (no pain) and 10 (severe pain) (Ballard et al., 2019).  
 It is clearly seen that these scales can be used in all different age ranges, but they can also 
be used from a different perspective. The FLACC scale, is often reported based off of an 
observer-reported perspective. That is the observer or health care professional assesses the 
patient and gives the patient a certain score for pain based off of the patient’s behavior (Ballard 
et al., 2019). The Wong Baker Faces Scale and Visual Analog Scale are both scales used from 
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the patient perspective, parent perspective, or observer. All of these different perspectives were 
used throughout research when assessing Buzzy® and the amount of pain the child experienced 
during the needle procedure or immediately after the procedure was completed (Ballard et al., 
2019).  
 Age specific.  
 The age for the use of Buzzy® during needle-based procedures has not been verified, 
however, research has shown that Buzzy® tends to work best in children that are younger than 
nine years of age. After nine, children are able to be distracted using more visual aids like video 
games or cartoons (Bergomi et al., 2018). However, there is still evidence to support the use of 
Buzzy® throughout the lifespan, including children of all ages (between 0 and 18). Much of the 
research conducted is associated with children that are at least three years of age and range up to 
12 years of age. This is the most commonly used age range because it allows researchers to only 
use one pain rating scale, as well as children are able report their own pain by this age (Ballard et 
al., 2019; Canbulat et al., 2015).  
Best Practice Model Recommendation 
 Based on the reviewed literature, for children under seven undergoing immunization the 
use of Buzzy® is highly recommended in helping to reduce pain. While, anxiety is also a huge 
reason for the use of Buzzy®, pain is the primary measurement throughout research, thus the 
focus for using Buzzy® is primarily on the management of pain (Inal & Kelleci, 2014). Buzzy® 
was specifically useful in ages younger than nine, as previously mentioned, children older than 
nine tend to have less pain when distracting using something visual (Bergomi et al., 2018). 
Additionally, when addressing what pain scale to use when assessing pain during needle-based 
procedures the use of the Wong Baker Faces Scale was ideal for children over three years of age. 
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It was also the most frequently used scale since it has good reliability and validity (Ballard et al., 
2019; Canbulat Sahiner et al., 2015). However, when looking at children less than three, the 
FLACC scale was also proven to be beneficial in measuring pain from the observer’s point of 
view (Ballard et al., 2019).  
 Buzzy® has been proven to be useful for many kinds of needle-based procedures, 
however, the most commonly performed needle-based procedure in the outpatient family care 
practice involving pediatric patients is vaccinations (Redfern et al., 2018). With vaccinations at 
the focus, Buzzy® will be used according to the recommendations in best practice. The Buzzy® 
wings will be removed from the freezer a couple minutes prior to the procedure and connected to 
the vibrating body. The child will be allowed to play with the Buzzy® device so that they feel 
comfortable with it. The Buzzy® device will then be applied to the site for stimulation for 30 
seconds. When the vaccination is to be given, Buzzy® will be moved about three to five 
centimeters above the site and continue through the end of the procedure (Ballard et al., 2019; 
Redfern et al., 2018).  
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CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE 
 Initiating a change in practice was created to help improve patient compliance, pain 
perception, and overall patient experience in pediatric patients receiving vaccination. In recent 
years there has been more research focused on controlling pediatric pain during needle-based 
procedures to help improve patient experience and decrease needle phobias. Needle phobias as a 
child has been shown to be positively correlated with noncompliance in adult patients (Ballard et 
al., 2019). One terrible needle-based experience as a young child can lead to years or decades of 
fear. Thus, increasing the need for an intervention and change in practice to help fight the rising 
numbers of patients with needle phobias. 
Participants and Setting 
 This EBP project took place at a family practice office in the northern part of Indiana. 
The office sees an array of ages across the lifespan, as well as a variety of care between common 
and complex patient diagnoses. There are two providers in the practice, a masters-prepared NP 
and a physician. The office is part of a larger healthcare organization that owns the practice, 
however, it is run by the one physician in the practice. This physician has over 20 years of 
experience in practice, while the NP has over 2 years of experience. The physician in the practice 
was selected as the project preceptor for this EBP project. The project preceptor granted 
implementation of the EBP project on May 23, 2019, which was also approved by the preceptor 
liaison for the healthcare organization, as well as the office manager. For a family practice office, 
this office sees a high number of children in need of vaccinations during their well-child visits. 
Since this case is true, it made the project preceptor understand how important it was to improve 
patient satisfaction by limiting the fear and pain that is associated with vaccinations. 
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 Vaccinations in the office are given by any of the four medical assistants on staff at the 
practice. All the medical assistant staff members are trained to give vaccinations and are 
competent to give vaccinations to a person of any age. Currently, the medical assistants do not 
participate in any sort of comfort measure during vaccination, nor do they measure the amount of 
pain the person endures during the procedure. The medical assistants widely accepted the 
practice change and implementation of the use of the Buzzy® device during vaccination.  
 The participants for this project were recruited during their appointments for routine 
vaccination during either a well-child visit or a simple nurse visit for an immunization. The age 
range of participants is from zero to seven, as those are the years when children receive the most 
vaccinations, as well as when the needle fear starts to be introduced. The participants can be 
male or female gender and come from any demographic or race background. The participant’s 
parents must have the ability to speak and understand spoken and written English to sign the 
consent form for using the Buzzy® device. The number of injections required during the 
appointment was not a factor in either inclusion or exclusion from this project. Participants that 
were excluded from the project included those that have a history of extreme sensitivity to 
coldness; nerve damage present that would affect the extremity being injected; 
neurodevelopmental delays or verbal difficulties; or there was a break or abrasion in the skin 
where the device would be placed during the procedure.  
Pre-Intervention Group Characteristics 
 Prior to implementation of the Buzzy® device, four weeks of measuring pain among 
children newborn to seven was completed. The pre-intervention group consisted of 12 
participants that received routine vaccinations. The group was made up of six females and six 
males with a range of ages from the youngest at two months and the oldest four years. The most 
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common age was two years or 24 months. Of the 12 participants, eight of the participants were 
under three years of age with four then being three years and older; meaning eight participants 
had their pain level measured using the FLACC scale, while the other four were measured using 
the Wong Baker Faces Scale. The participants did not have a previous history of painful 
procedures, however, there was a difference in the number of shots given; 8 of the 12 
participants received four vaccinations, one received three vaccinations, two received two 
vaccinations, and one received one vaccination. Among the participants, there was not a 
significant variation in race. A majority of the participants were Caucasian, making up nine of 
the pre-intervention participants. The other three participants consisted of two African 
Americans and one that is unknown.  
Intervention 
 The intervention for this project was developed based on EBP recommendations and 
from these, a detailed protocol and/or implementation guideline was created for use during 
vaccination. The intervention includes the use of cryotherapy and vibration in the form of the 
Buzzy® device. The combination of intervention has been proven highly effective, as it 
combines two different ways of interrupting nerve impulse. Since the combination therapy has 
been shown to be most effective, it was thus implemented into practice.   
 Upon arrival to the practice, patients that met the inclusion criteria were asked to join the 
project via parental approval. The legal guardian of the patient was requested to sign a consent 
form prior to the implementation of the Buzzy® device (see Appendix B). If the consent was 
signed, then the child and/or parent played with the Buzzy® device prior to injection, so that 
they felt comfortable with the product. While the child and/or parent was becoming acquainted 
with the device, the icepack wings were removed for a couple minutes of thawing prior to 
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placement on the participant’s skin. When the participant was ready for the procedure to begin, 
the Buzzy® device was placed on the injection site. The device was vibrating, while also cooling 
with the icepack portion of the device. It remained on the site for 30 seconds prior to injection. 
When the injection was taking place, the device was moved just above the site still continuing to 
vibrate and providing cold therapy. The injection was then given to the participant. Immediately 
after the vaccination was completed, the participant was scored for pain that was experienced. In 
children that were younger than three years of age, the Face, Legs, Activity, Cry, and 
Consolability Scale (FLACC Scale) was used to assess the pain. While, children that were over 
three years of age were assessed using the Wong-Baker Faces Pain Rating Scale. After the 
assessment was completed, the medical assistant placed the pain score in the patient’s electronic 
medical record.  
 Prior to the start of implementation of the intervention a brief in-service was completed to 
educate the medical assistances and the providers on the use of the Buzzy® device. A 
PowerPoint presentation was completed to inform the staff about how the Buzzy® device 
worked, how to use the different pain scales, and what would be required for documentation in 
the electronic medical record. Throughout the project reminders were emailed and food 
incentives were given to let the staff know the progress with the project, as well as the 
appreciation for participation in this practice change.  
Comparison 
 Prior to implementation of the intervention, data were collected for four weeks to obtain 
the average pain rating score of children receiving vaccinations that were between the ages of 
zero and seven years. The reason that this comparison is taking place is to identify not only the 
need for an intervention for pain, but also to assess how high the average pain (FACES Scale 
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participants) and/or how the behavior of pain (FLACC Scale participants) was compared to the 
post-intervention group. Currently, the practice has no comfort measures in place for children 
that are receiving routine vaccination. Since, vaccinations are the largest routine pain-producing 
procedure in children it is important to identify interventions that can help limit the pain that is 
afflicted during these procedures.  
Outcomes 
 The primary outcome that has been identified for the project is pain rating after injection. 
Children that are under three years of age, will be assessed using the FLACC Scale. The FLACC 
Scale instructions include five parts that are: face, legs, activity, cry, and consolability. The 
participant is given a rating for each part that ranges from a zero to two. The minimum pain 
score is a zero and the maximum score is a 10. The participant has zero pain if their face has no 
particular expression or smile; their legs are normal position or relaxed; they are lying quietly 
with normal position and moves easily; the person is not crying; and the participant appears 
content and relaxed. The maximum score of a 10 consists of the participant having frequent to 
constant quivering chin and clenched jaw; kicking or drawn-up legs; arched, rigid, or jerking; 
crying steadily, screams, sobs, and frequent complains; and difficulty to console or comfort (The 
Department of Health, 2013a). Often children fall somewhere between these two extremes. For 
example, a child may show a grimaced facial expression (rating 1), with relaxed legs (rating 0), 
body that is tense (rating 1), a small whimper (rating 1), and appears to be reassured when held 
(rating 1). For this child, the score would indicate a pain rating of four, however this is from 
simple observation of behavior. This scale is used when self-reported pain is not possible, which 
is the case with children that are under three. Children under three do not have the capacity to 
understand how to rate their own pain, thus the FLACC scale is an interpretation of pain 
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behavior. It takes careful decision and observation of pain behaviors in order to indicate what the 
pain score may be for the specific patient. According to The Department of Health (2013a), the 
instructions for using this assessment tool include: observing the person for at least two to five 
minutes, observe legs and body uncovered, reposition patient or observe activity, and finally 
initiate consoling intervention if needed.  
 The FLACC Scale has readily been used in children and critically ill adults that are 
unable to verbally report pain. There are several studies that have looked at the reliability and 
validity of the FLACC Scale. In one such study, the FLACC score correlated significantly with 
Checklist of Nonverbal Pain Indicators (CNPI) scores, thus supporting excellent criterion 
validity in adults (p = 0.963; P < .01). Additionally, the FLACC Scale and another pain scale 
called COMFORT were highly correlated (p = 0.849; P < .01), supporting criterion validity in 
children (Voepel-Lewis, Zanotti, Dammeyer, & Merkel, 2010). Using the same study, reliability 
was proven to be significant as well. It was proven that agreement among each of the observers 
was excellent for each category in the FLACC Scale, as well as for the total FLACC score. This 
supports the interrater reliability of the tool for assessing pain. Finally, internal consistency was 
excellent with a Cronbach alpha of 0.882 (Voepel-Lewis et al., 2010).  
 In addition to the FLACC Scale, the Wong-Baker FACES Scale was also used to assess 
pain in children that were old than three years of age. The tool was originally created with 
children for children to help them communicate their pain. The scale has a series of faces that 
range from a happy face at zero to a crying face at 10. Again, children often fall somewhere 
between these two extremes of “no hurt” to “hurts like the worst pain” (Wong-Baker FACES 
Foundation, 2016). The child is given an explanation that each face is for a person who feels 
happy because he/she has no pain (hurt) or sad because he/she has some or a lot of pain. The 
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child is then asked after the procedure what face best describes how he/she is feeling (The 
Department of Health, 2013b). 
 The Wong-Baker FACES Pain Rating Scale has been used in multiple research studies 
involving children over three years of age. One study conducted in an emergency department 
focused on the validity of the Wong-Baker FACES Scale (Garra et al., 2010). The Wong-Baker 
FACES Scale was tested for correlation with the Visual Analog Scale (VAS), a scale that is 
similar but does not include visual faces to show what the pain may look like for the patient. A 
test for homogeneity of variance across the FACES Scale categories was not significant. 
Additionally, agreement between the FACES Scale and the VAS was excellent (p = 0.90; CI = 
0.86 to 0.93) (Garra et al., 2010). For reliability of the FACES Scale, a systematic review was 
examined that looked closely at three different “face” scales, one of them being the Wong-Baker 
FACES Scale. It was determined that the test-retest reliability was r > 0.5 and correlation 
between self-report and observational scores were r > 0.4. Furthermore, when children were 
given the choice between faces scales, they preferred the Wong-Baker FACES Scale over all 
other face scales (Tomlinson, von Baeyer, Stinson, & Lillian, 2010).  
 Using both of these pain rating scales, data were collected by the medical assistants who 
gave the vaccination. After the vaccination was given, the medical assistants assessed the pain 
rating score using the appropriate scales. Once the rating was determined, the medical assistant 
documented the pain rating score in the participant’s electronic medical record, along with what 
scale was used for the patient.  
 Demographic information for the project was collected using the electronic medical 
record. The project manager looked closely at the child’s age, racial differences, and if there has 
BUZZY® DEVICE FOR VACCINATIONS   
 
43 
been any experiences of painful surgeries or procedures in the past. These past experiences could 
affect how the child experiences pain now, thus making the it an important factor to measure.  
 Following the completion of the implementation of the intervention, the project manager 
collected the data from the electronical medical record for analyzing. The data were not removed 
from the electronic medical record or taken to the project manager’s home. All the data 
collection took place at the project site, as there was no access to the health system’s electronic 
medical records outside of the project site. Once all the data were collected, the pre-intervention 
and post-intervention pain scores were analyzed via chi-square of independence. The 
demographic data were also analyzed using Chi-square and t-test for independence.  
Time 
 The project timeline lasted for eight weeks starting on August 26th, 2019 and going until 
October 18th, 2019. The first four weeks of the project was focused on collecting preliminary 
data. Since the office currently does not use any pain tools to assess pain during vaccinations, the 
project manager collected data on pain ratings prior to the use of the Buzzy® device. The project 
manager also collected demographic information to assess for the variation in race, ages that are 
seen most often, and painful procedures (surgeries, broken bones, dental procedures, and other 
painful experiences). Following the four weeks of pre-intervention, the Buzzy® device was 
implemented for four weeks to assess pain rating scores post-intervention. The reason this time 
of year was selected was due to the increase of influenza vaccinations given during the fall 
months.  
Protection of Human Subjects 
 Throughout the entirety of the project human subjects were protected from any risk or 
harm. The project manager went through the proper education for protection of human subjects, 
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as well as completed an ethics course through a certified DNP program in the fall of 2018. The 
CITI Program entitled, “Social Behavioral Educational Research: Basic Course” was also 
completed in April 2019 by the project manager to fulfil the Valparaiso University requirements 
to begin this project. The project manager completed an Institutional Review Board (IRB) 
Questionnaire in July 2019 to plan what sort of review was expected for this project. Upon 
completion, the exemption form for Valparaiso University IRB was completed per the 
questionnaire response on July 17, 2019. Prior to implementation of the Buzzy® device, the 
participants and parents/legal guardian were thoroughly educated on the device, the project, and 
the risk factors associated with participation. Any questions that the participant or legal guardian 
had about the project were completely answered. If the legal guardian approved that their child 
could participate then consent was obtained by the legal guardian. The participants and guardians 
were informed that confidentiality would be upheld, that participation was completely voluntary, 
and if at any point they did not want to participate they would be exempt without issue. The data 
from the participants were collected in the health care system’s electronic medical records and 
are secure via password protection. Following this collection, the data were entered into the 
project manager’s personal computer. The participants did have any personal identifiers in the 
project manager’s personal computer. The computer was password protected both on the home 
screen, as well as in the analysis program to help insure protection of any participant 
information.  
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CHAPTER 4 
FINDINGS 
The purpose of this EBP project was to implement the use of cryotherapy and vibration 
via the use of the Buzzy® device in order to improve patient comfort and reduce pain that is 
associated with receiving a vaccination. Patient outcomes were measured using the FLACC pain 
rating scale for children two years and under, as well as the FACES pain rating scale for children 
three years and older. The baseline pain scores were collected over four weeks prior to the 
implementation of the Buzzy® device. Once implemented, pain was once again measured for 
another four weeks. Analyzation was completed for both demographic characteristic and pain 
score comparison.  
Participants 
Size. During the implementation of the project, there were a total of 16 participants that 
received guardian consent for the use of the Buzzy® device during vaccination. Each of the 
participants had recorded pain scores that were associated with their respective ages and scales 
that were used. Likewise, the pre-intervention group was measured in the same way, however 
there were only 12 participants in total in that group.  
Demographics. Demographic characteristics were collected for the post-intervention 
group using the same process as the pre-intervention group. A thorough search of the electronic 
medical records provided the information for gender, age, race, previous painful procedures, and 
the number of vaccinations received during the visit. The post-intervention group consisted of 10 
females and 6 males. The age range of the post-intervention group was two months to five years 
of age, with the most common age being four months. Of those who participated, 10 were 
measured using the FLACC pain scale and 6 were measured using the FACES pain scale. Like 
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the pre-intervention group, none of the participants had a history of previously painful 
procedures. The number of vaccinations that were given ranged from one vaccine to five 
vaccines. There were four participants that received one vaccine, seven received three vaccines, 
four received four vaccines, and one received five vaccines. The race of the post-intervention 
participants included nine Caucasians, two African Americans, three Hispanics, and two 
unknowns. Descriptive statistics regarding pre-intervention and post-intervention demographic 
data are presented in Table 4.1. 
Changes in Outcomes 
  This EBP project addressed the following PICOT question, “In pediatric patients, under 
7 years of age, receiving routine vaccinations (P), what is the effectiveness of using non-
pharmacological Buzzy® device (I) compared to standard practice of no comfort policy (C) in 
helping to promote a decrease in pain measured by the FLACC or Wong-Baker Faces Scale (O) 
during an eight-week period (T)? The primary outcome of pain was measuring using either the 
FLACC scale for those two years and under or the Wong-Baker Faces Scale for those three years 
and older.  
 Statistical testing. Data were entered into the Statistical Package for Social Sciences 
(SPSS) Version 22 for statistical analysis. The text How to use SPSS: A step-by-step guide to 
analysis and interpretation by Cronk (2017) was also utilized to help guide the process of 
analysis and interpretation of project data. A t-test was completed for comparison of pre-
intervention and post-intervention pain scored for both pain scales. A t-test was also used to 
compare pre-intervention and post-intervention demographic information on patient age and 
number of vaccinations. A chi-square statistical analysis was completed for comparison of the 
rest of the demographic information which included patient gender, previous painful procedure,  
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Table 4.1 
Demographic Characteristics 
Demographic Pre-Intervention Frequency (%) Post-Intervention Frequency (%) 
Number of 
Participants 
12 (100%) 16(100%) 
 
Age 
 
Mean/SD 
Range 
 
 
 
 
24 months/2.23 
2 months – 4 years 
 
 
 
21 months/2.87 
2 months – 5 years 
Gender 
Male 
Female 
 
 
 
 
6 (50) 
6 (50) 
 
 
6 (37.5) 
10 (62.5) 
 
# of Vaccinations 
1 Shot 
2 Shots 
3 Shots 
4 Shots  
5 Shots 
 
1 (8) 
2 (17) 
1 (8) 
8 (67) 
0 (0) 
 
4 (25) 
0 (0) 
7 (44) 
4 (25) 
1 (6) 
 
Race 
Caucasian 
African American 
Hispanic 
Unknown 
 
 
 
9 (75) 
2 (17) 
0 (0) 
1 (8) 
 
 
9 (56) 
2 (12.5) 
3 (19) 
2 (12.5) 
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and patient race. Statistical significance for all analyses was determined as p < 0.05.  
 FLACC scale. The perception of pain for children two years and younger was scored 
using the FLACC scale, which rates pain based on five different items that are ranked with a 
score of zero to two for each item. These five items include face, legs, activity, cry, and 
consolability. The participants pain was rated based on their facial expression following 
vaccination, the restlessness of their legs, their overall squirminess, the amount of crying, and 
finally, their ability to be easily consoled. The total of these items adds up to a score between 0 
and 10, with 0 being rated as no observed pain to 10 being severe pain observed following 
vaccination. A chi-square for independence was completed to compare scores from the pre-
intervention group to the post-intervention group. The mean for the pre-intervention group was 
4.5 (sd = 2.2), and the mean for the post-intervention group was 1.2 (sd = 0.41). A significant 
difference between the pre-intervention and post-intervention group was found (x2(4, N=18) = 
12.48, p < 0.05). 
 FACES scale. Participants that were three years and older, scored their pain rating using 
the Wong-Baker FACES scale. This scale rates pain on a scale from 0 to 10 using increments of 
two. Each number coincides with a picture of a cartoon face depicting the amount of pain that the 
participant might be in after vaccination. The participant was asked to select which pictures 
accurately depicts the amount of pain that was experienced. A chi-square for independence was 
completed to compare scores from the pre-intervention group to the post-intervention group. The 
mean for the pre-intervention group was 3.5 (sd = 0.71), and the mean for the post-intervention 
group was 1.5 (sd = 0.71). No significant difference between the pre- and post-intervention 
group was found (x2(3, N=10) = 5.94, p > 0.05). 
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 Demographic stats. To make an accurate comparison of the two groups it was important 
to verify that the groups were similar in regard to their age, number of vaccinations given, race, 
and previous history of a painful procedure. A t-test was completed to compare both the pre- and 
post-intervention ages and number of vaccinations. The participants in the pre-intervention group 
had a mean age of 24 months (sd = 2.23), and the mean age of the post-intervention group was 
21 months (sd = 2.87). No significant difference was found between the pre- and post-
intervention group ages (t(11, N=28) = 0.799, p > 0.05). Likewise, there was no significant 
difference found when comparing the number of vaccinations (t(11, N=28) = 1.23, p >0.05). The 
mean for the pre-intervention number of vaccinations was 3.3 (sd = 1.07), and the mean for the 
post-intervention number of vaccinations was 2.7 (sd = 1.37). The rest of the demographic 
information was compared using chi-square analysis. A chi-square test of independence was 
calculated comparing the genders of both the pre- and post-intervention groups. No significant 
relationship or difference was found between the two groups (x2(1, N=28) = 0.438, p > 0.05). 
Another chi-square of independence was calculated comparing the race of both the pre- and post-
intervention groups. Again, no significant relationship or difference was found (x2(3, N=28) = 
2.82, p > 0.05). Participants in both groups had never experienced a previously pain procedures, 
and therefore there was not a need for any statically significant analysis as both groups were 
exactly same in this case.  
 Reliability and validity. The reliability and validity of each tool utilized to evaluate pain 
outcomes was assessed. The FLACC scale was used to evaluate pain for participants two years 
and younger, while the Wong-Baker FACES scale was used to evaluate pain for participants 
three years and older. There is consistent evidence to support the reliability and validity of the 
FLACC scale (Voepel-Lewis et al., 2010). The FLACC and FACES scale were tested for 
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validity through the comparison of associating the two scales together. A Pearson Correlation 
was computed to show the reliability of the FLACC and FACES scales. The results were 
considered medium reliability with a score of 0.635. The FLACC scale could not be tested for 
validity due to each item in the scale having an individual score, and for this project only a total 
number was computed therefore it cannot be tested against other like scales. Though, it has been 
thoroughly tested for validity in the literature. Likewise, the FACES scale was not able to be 
tested for validity due to similar circumstances, as well as the inability to extract specific data 
from other studies that were completed in a similar way. Although, the FACES scale has been 
used numerous times in literature and is considered very valid in other studies.  
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CHAPTER 5 
DISCUSSION 
This EBP project served the purpose of answering the PICOT question, “In pediatric 
patients, under 7 years of age, receiving routine vaccinations (P), what is the effectiveness of 
using non-pharmacological Buzzy® device (I) compared to standard practice of no comfort 
policy (C) in helping to promote a decrease in pain measured by the FLACC or Wong-Baker 
Faces Scale (O) during an eight-week period (T)?” The project specifically examined the impact 
of using cryotherapy and vibration protocol via the Buzzy® device during vaccinations, and the 
possible improvement of pain and/or comfort through the use of such interventions. This chapter 
will thoroughly explain and interpret the project findings, as well as evaluate the application of 
the EBP model which was used to help guide this project. Project strengths and limitations will 
be discussed, along with consideration of implications for future practice, theory, research, and 
education.  
Explanation of Findings 
 The project findings somewhat supported the effectiveness of combining cryotherapy and 
vibration for pain comfort during vaccinations for children under seven years of age. The results 
were consistent with the literature for children that were under three years of age, but 
inconsistent with the literature for children that were aged three years to seven years. Participant 
findings, which include sample size and demographic characteristics, will be discussed. 
Outcomes for the individual pain tools will also be explained.  
Participant Findings  
 The information reported within the high quality, current literature, included a larger 
sample size of participants undergoing needle-based procedures using the Buzzy® device, thus a 
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larger sample size for this project was expected. The sample size was more limited due to the 
specific age range that was included in this project, whereas in the literature reviewed the 
inclusion population typically consisted of children newborn to 18 years of age. The sample 
population for the pre-intervention group was equal among males and females, whereas the post-
intervention group included more females than males. This was consistent with all of the 
literature reviewed, as there was not a consistent number of males or females used in any of the 
studies. Some of the literature reviewed had more females, while other studies had more males 
that were included. Likewise, the literature that was reviewed included no significant difference 
between the pre-intervention and post-intervention groups, which was consistent with the results 
of this project. Only one of the reviewed literature included race as a demographic feature. The 
participants within that study included more African American participants compared to this 
project that was predominately Caucasian. The reviewed study was completed in Toledo, OH 
where the population is 65% Caucasian and 27% African American (Redfern et al.,), which is 
surprising considering the larger number of African American patients that were seen. However, 
for this project, the larger number of Caucasian included was consistent with the population in 
the area. The studies that reviewed the number of vaccinations given were also consistent with 
the number reported for this project. There was a larger mixture of anywhere from one to five 
vaccines given in the literature review, which was seen in this EBP project as well. In the 
literature review and in this project, there was no evidence to suggest previous painful 
procedures and essential leaving no data for comparison.  
Pain Results 
 Statistically significant results were found when the FLACC pre-intervention group was 
compared to the FLACC post-intervention group. The group consisted of children that were 
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under three years of age. The mean score for the 8 participants in the pre-intervention group was 
4.5, while the mean score for the 10 participants in the post-intervention group was 1.2. The 
scores recorded indicated a decrease in pain when using the Buzzy® device for vaccinations. The 
results of this portion of the EBP project were consistent with results found in the literature 
review as it concludes that use of the Buzzy® device for younger children was seen to produce 
significant reduction in pain (Ballard et al., 2019). Thus, the statistical decrease in pain scores 
achieved supports the benefit of using the Buzzy® device for comfort when children younger 
than three years of age receive vaccinations.  
 While the children under three years of age were considered to have significant results, 
those that were between the ages of three and seven, using the FACES scale for pain, were not 
considered significant in this project. However, the lack of statistical significance does not 
exclude the positive impact that the Buzzy® device has on pain during vaccinations. The mean 
score for the four participants in the pre-intervention group was 3.5, while the mean score for the 
six participants in the post-intervention group was 1.5. These mean scores indicate that there was 
a decrease in pain between the two groups even though it was not considered significant. Part of 
the reason for the lack of significances may be due to the smaller sample size, as compared to the 
FLACC group. The FACES group only had a total of 10 participants included in both groups, 
while the FLACC group had 18 participants in total. The lack of participants is a possible reason 
for the lack of significance in results. Additionally, the literature that was reviewed included far 
larger sample sizes when compared to this project, which may account for the fact that those 
results were all considered to be significant. While the results were surprising, there was still one 
study that did indicant that the Buzzy® device was more effective in younger aged children. The 
reasoning could be that younger children are more easily distracted, while older children may be 
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more focused on the needle (Moadad et al., 2016). The distractibility of the younger participants 
in this project may have played a role in the significant results for the FLACC group, and the 
absence of significant for the older participants in the FACES group. Therefore, the results of 
this project in no way indicate the impact that the Buzzy® device can have for future practice. 
The decrease in mean score of pain between the two groups indicates that the Buzzy® device 
was still effective in providing pain relief and was a great benefit to the participants, even though 
it was not significant.  
Strengths and Limitations of the DNP Project 
 The Johns Hopkins Evidence Based Practice Model (JHNEBPM) served as the EBP 
model that guided the project. The use of this model aided in the effective implementation of the 
practice change by providing a framework that the project manager could follow. The successful 
implementation and results of this EBP project yielded numerous strengths, as well as some 
limitations. By addressing both the strengths and the limitations of this project, results of this 
project may be further explained and future related projects may be supported.  
Strengths of EBP Framework  
 The JHNEBPM was a good fit as the EBP framework utilized in guiding this EBP 
project. The project manager was a beginner in regard to project planning, practice change, 
implementation, and overall evaluation. Therefore, the detailed steps included in the JHNEBPM 
aided in the consideration of specific aspects of the project that otherwise may have been missed 
or disregarded. The JHNEBPM is comprised of three phases that include: practice questions, 
evidence, and translation. Within the three phases there are 19 steps that were followed through 
the implementation of this EBP project (Dang & Dearholt, 2017; Melnyk & Fineout-Overhold, 
2015). The basic premise of the EBP project was created through the use of the practice question 
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phase. This phase addressed the identification of the practice problem, issue, or concern that was 
important for implementation into practice. During experiences within the clinical setting in 
family practice, the project manager noticed the lack of comfort provided to children during 
vaccinations apart from family members holding or attempting to comfort the child. After 
thoroughly study and research for possible solutions for providing comfort, there was strong 
evidence to support the use of the Buzzy® device. The practice change was then suggested to a 
Northern Indiana family practice office that immediately developed a plan for the project to 
unfold. A professional team was formed and the specific EBP question was developed. Evidence 
was then collected through the evidence phase of the EBP model. All areas of evidence were 
searched for further evidence to support the use of Buzzy® in practice. Once the evidence was 
found it was appraised and the quality of each evidence was determined. Summarizing and 
synthesis of the evidence was completed to help with the development of recommendations for 
change. The project manager then develop a small educational in-service to discuss the 
translation into practice. Together, the practice team determined if the change was feasible and 
appropriate for their specific practice. A plan of action was addressed with the team and the 
suggestions for how the project would operate were discussed. The project site graciously 
invested in the Buzzy® devices for the project and for future use. During the implementation of 
the project, most went according to planned. However, the project manager had to send out 
emails to frequently remind staff to use the Buzzy® device during the required weeks, as well as 
recording the respective pain scores in the EMR. Additionally, one of the key stakeholders in the 
practice change quit half-way through the implementation, which made the project more difficult 
as there were many new staff members that were not educated on the change that joined the 
practice site during the project. Modifications were made, and the project manager addressed the 
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use of the Buzzy® device with the new staff members. Overall, the results of the project were 
evaluated through the review of the EMR and then run through SPSS for statistical significance. 
The findings of the project were then reported to the key stakeholders and next steps for 
dissemination of the findings were determined. Thus far, the project site has adopted the change 
to practice and continues to use the Buzzy® device for vaccinations, as well as routine blood 
draws on children and adults.  
Strengths of the Project 
 There were several strengths of this project that were evident. One of the largest strengths 
was the support from the clinical staff and site facilitator.  They greatly believed in the need for 
practice change and were excited to introduce the Buzzy® device to their patients. This made the 
project more successful in that they were willing to make the change. Similarly, patients and 
their guardians willingly accepted the use of the Buzzy® device. Several guardians expressed 
great satisfaction and a noticeable difference in their child during vaccination. The project would 
not have been possible if the participants had not been so enthusiastic about the project. Another 
strength of the project was the simplicity of the project itself. The project was very easy to 
understand and not extremely time consuming for the staff. This allowed for the project to be 
realistic in the busy family practice setting. Likewise, with only measuring one outcome it made 
it easy for the staff to learn the respective pain scales and place the pain score in the EMR. Only 
measuring a single outcome also made data collection and analysis more straightforward. An 
additional strength was also the affordability of the Buzzy® device. The Buzzy® device can 
easily be cleaned off for reuse, making it a great product for busy healthcare facilities that do not 
want to spend excessive amounts of money on new products for every patient. Although a 
statistically significant difference was not achieved for children between the ages of three and 
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seven, this in no way negates the positive impact of the project. As was previously seen, the 
mean pain score for these children did decrease showing that the Buzzy® device was effective. 
A statistically significant decrease in pain scores did occur in children that were younger than 
three years of age. Thus, the overall results of this project were similar to those reported in high 
quality evidence based on the review of literature.  
Limitations 
 Despite the strengths of this project, there were several limitations worth noting. The 
small sample size was certainly a limitation to this project. The small sample size was 
constrained by the short timeline of the project. Additionally, to get a more accurate difference in 
pain scores it would have been more beneficial to have the same participants for both the pre-
intervention and post-intervention groups. However, the short timeline of the project made it 
difficult as the participants would not need more vaccinations so close together. Of course, the 
project was not randomized or a double-blind project because the children and/or guardians that 
participated knew they were receiving the use of the Buzzy® device, as well as the 
providers/staff knew the participants in the project. The providers and staff were informed of the 
possible hypothesis, as well as literature review results. This could have caused some bias in 
reporting of pain scores between the two groups. The staff was also not randomly selected which 
may have influenced the usual care process. In addition, the project manager was unable to be at 
the clinic during every child’s vaccination due to conflicts schedules. That being said, the staff 
had to be aware of gaining consents and using the correct pain scoring scale for each participant. 
There were some situations where consents were not obtained or scores were not recorded in the 
EMR, thus causing a smaller sample size. There was also a key staff member that quit halfway 
through the project implementation, which led to further loss of participants due to new 
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employmees not knowing about the project. Finally, during the dissemination portion of the 
project there was a pandemic of Coronavirus that broke out in the Northern Indiana region 
causing the project manager to have limited access to the clinic site. However, via conference 
calls the project manager was still able to communicate with essential staff about how to carry 
out future practice with the use of the Buzzy® device.  
Implications for the Future 
 This EBP project provided valuable information for the advanced practice nursing 
profession related to pain relief during vaccinations for children. Future implications for practice, 
theory, research, and education will be discussed. Such implications can be used to help guide 
and improve future EBP projects and practice changes, that will positively influence the way 
pain can be treated during vaccinations.  
Practice 
 The combination of cryotherapy and vibration through the use of the Buzzy® device has 
been established as one of many best practice options for pain during needle-based procedures in 
current, high quality literature. This project allowed for the Buzzy® device to become 
standardized practice during vaccinations at the project site. It was also encouraged for all family 
and pediatric practices within the organization to adopt this protocol for children receiving 
vaccinations. This project was supported by the clinical site, and the cost of the Buzzy® devices 
that were purchased for the project were covered by the clinical site. Other practice sites within 
the organization have started the process of purchasing Buzzy® devices for their practice. The 
benefit of the Buzzy® device is that they are relatively inexpensive and reusable making them 
last longer than a single patient use.  
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 For future EBP projects or related activities there are several considerations to be 
addressed. Future projects related to the use of Buzzy® device would benefit from a larger 
sample size and if possible include the same participants for both groups to see if the Buzzy® 
device has an increased impact on pain scores. Additional recommendations for future projects 
could include further comparison of the Buzzy® device with other pharmacological and non-
pharmacological methods to further standardize the Buzzy® device as the most effective 
treatment for pain during needle-based procedures. Further comparison could also be completed 
for all needle-based procedures using the Buzzy® device to seek answers about which needle-
based procedure is most effect for the use of Buzzy®. It would also be beneficial for future EBP 
projects to explore the use of cryotherapy and vibration on adults as the Buzzy® device may be 
helpful for pain and anxiety during those needle-based procedures as well.  
Theory 
 The use of the JHNEBPM for the framework for this EBP project was help in the 
successful implementation of the Buzzy® device into practice. It allowed for all areas of this 
project to be fulfilled to the greatest extent, as specific details may have been lost without the 
guidance from this model. Future projects could also utilize the concepts derived from the 
JHNEBPM. The model provides detailed steps for the implementation of change into practice in 
several different specialty areas for inpatient and outpatient settings. However, this model is 
quite rigorous as it does involve 19 steps within the three phases, future EBP projects would 
have to take this into consideration when selecting a model.  
 Future projects may also consider the use of a theoretical foundation to aide in successful 
implementation. While not in use for this project, Kolcaba’s Theory of Comfort may be a great 
asset for use in future EBP projects. Kolcaba’s Theory describes comfort as existing in three 
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forms: relief, ease, and transcendence. The basis of the theory surrounds the idea that specific 
comfort needs of a patient are met then the patient experiences comfort in the sense of relief. 
Ease addresses comfort in a state of contentment. Finally, transcendence is described as a state of 
comfort in which the patient is able to rise above their challenges. These basic ideas are woven 
together in the model that addresses the specific health care need, the intervening variable 
needed for comfort, comfort itself, the health seeking behaviors, the institutional integrity, and 
best practice/best policies for protocol (Kolcaba & DiMarco, 2005). The use of Kolcaba’s 
Theory of Comfort would be an excellent fit for future EBP projects dealing with pain, as it 
allows for deeper exploration while still upholding the importance of holistic and patient-
centered care.  
Research 
 Further research is needed to explore the effects of Buzzy® device in comparison with 
other non-pharmacological and pharmacological intervention options for pain during needle-
based procedures. It may be that a combination of multiple distraction interventions is more 
effective that using Buzzy® alone. Although, the additional combination may prove to be too 
expensive for practices to sustain or too time consuming for busy practices. Thus, there would 
need to be further research to examine if the combination should become standard of practice. 
Additionally, further research should look closely at the use of the Buzzy® device in adults. 
While, needle fears do develop at a younger age, adults may still experience the effects of the 
fear that started as a child. If shown to be significant then Buzzy® could be used for all ages and 
all needle-based procedures.  
Education 
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 Patient education is an important task and responsibility of the advanced practice nurse. 
The participants were thoroughly educated on best practice treatment, possible side effects to the 
use of cryotherapy and vibration, and purpose of the combination therapy for this project. 
Education was also a main component for staff learning about this project. The staff required an 
in-service for education on the protocol for change that included the use of the Buzzy® device, 
as well as perspective pain scales used to assess pain. Additionally, a pamphlet of information 
from the Buzzy® device company was provided to the participants, which included stories of 
using the Buzzy® device and further statistical evidence of supporting its use in practice. All of 
this allowed the participants and staff to become well-informed about this project and the 
changes need for practice. This project brought incredible light to the importance of standard of 
practice education in area that is not as well research or studied. Therefore, educating through 
different resources available may increase the likelihood that others receive the pain relief 
needed during needle-based procedures.  
Conclusion 
 This EBP project has allowed the site facilitator, clinical staff, and project participants to 
see the value of using a combination of cryotherapy and vibration through the use of the Buzzy® 
device for pain during needle-base procedures, specifically vaccinations for this project. The site 
facilitator and practice manager have expressed their satisfaction with the project and plan to 
continue to use the device for future needle-based procedures. Additionally, the practice manager 
that oversees multiple sites plans to incorporate the device into practice at her other sites. 
Participants also expressed their approval of the use of the Buzzy® device and plan to use the 
device for future vaccinations. Participants were also encouraged to purchase self-use Buzzy® 
devices if they change practices and encourage friends with children to do the same.  
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 In conclusion, the results of this project supported the effectiveness of combination 
cryotherapy and vibration for vaccinations in children as was seen by the improvement in pain 
scores, which is consistent with current literature. While no statistical significance was achieved 
for children between the ages of three and seven, there was significance achieved in the children 
less than three years of age. Overall, in both the older and younger children mean scores for pain 
did decrease, indicating that the Buzzy® device did reduce pain even when not considered 
significant. Continuation of the use of the Buzzy® device was encouraged for best-practice 
purposes. Providers and clinical staff are recommended to incorporate this combination of 
cryotherapy and vibration protocol as an easy and cost-effective way to continue to provide 
comfort for those undergoing vaccinations and other needle-based procedure.  
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Appendix B 
Authorization & Consent for Use of Buzzy® Device 
 
Patient Name:       Birthdate:     
   
 
 
Project Title: What’s all the Buzzy® About? Using Cryotherapy and Vibration to Decrease Pain 
During Vaccinations in the Pediatric Population 
 
Project Manager: Marta Byma, BSN, RN, DNP Student Valparaiso University College of 
Nursing and Health Professions 
 
Purpose: This is a consent form for evidence-based practice participation. It contains important 
information about the project and what to expect if you (as the guardian) decide that your child 
may participate. Your child is being asked to join an evidence-based practice project for patients 
receiving a vaccination(s) that will help examine the effects of the Buzzy® device on pain during 
the procedure.  
 
Voluntary Participation/Withdrawal: Your child’s participation is voluntary. Please read and 
consider the information carefully. You may ask questions before making any decision regarding 
participation and at any time during and after the project’s implementation. If you decide that 
your child may participate, then you will be asked to indicate your child’s consent for 
participation with your (guardian) signature. Your child is allowed to leave the project at any 
time. There will be no penalty if you or your child makes the decision to be removed from the 
project. Your decision will not affect any relationship nor the care that is provided in the future at 
B****** Family Medicine.  
 
Procedure: If your child participates in this project, the child will be utilizing the Buzzy® 
device to decrease pain during vaccination. The child will be allowed to hold, touch, and play 
with the Buzzy® device prior to use during the procedure. Prior to injection, the Buzzy® icepack 
wings will be removed from the freezer to allow for a couple of minutes to warm before placing 
directly on the skin. The Buzzy® device will then be placed on the child’s injection location for 
30 seconds prior to injection. This will cause the area to be slightly numbed prior to injection. 
During the vaccination procedure, the Buzzy® device will be placed just above the injection site. 
The vibration and icepack will still be operating, allowing for distraction from the procedure. 
Following the vaccination process, the medical staff will measure the amount of pain that is 
reported. If your child is over three years old, the child will be asked to rate their pain on a 
FACES scale from 0 to 10. If your child is younger than three, then the staff will observe for 
pain using the FLACC scale, which means looking closely at their face, legs, arms, if they are 
crying, and how easily comforted they are after the procedure.  
 
Duration: If decided that your child will participate in this project, the duration is only one 
appointment time for vaccination. This is the only time that contact with the patient will occur, 
no follow-up is necessary.  
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Risk: The potential risk to participating in this project are minimal but can include side effects of 
skin contact with the coldness of an icepack. Additional safety concerns include discomfort 
associated with the vibration mechanism of the Buzzy® device.  
 
Benefits: The benefits of participating in this project include receiving care based on 
recommendations from evidence based practice that focuses on improving patient experience and 
pain relief. This project seeks to improve quality of care and improve patient satisfaction in all 
aspects of care. An additional goal, is to improve compliance with care and for your child to not 
fear a visit to the doctor’s office.  
 
Confidentiality: As the guardian, you understand that the all efforts will be made to keep 
project-related information confidential. However, there may situations where this information 
must be released, for example if information is released for state law purposes. In the event that 
there is any indication of self-harm or harm of others, it will be necessary to break confidentially 
for your child’s safety and the safety of others. Any information that contains your child’s 
identification information will be only accessible via electronic medical records. General 
information obtained from this project may be utilized in nursing journals, presentations, or other 
publications, but no one will be able to identify your child’s information as no patient identifiers 
will be released.  
 
Contacts and Questions: For questions and concerns about the project. You may contact the 
project manager, Marta Byma, at (269) 203-5276 or marta.byma@valpo.edu. You may also 
contact D. B*****, with questions at his office (574) 848-4039. Christina Cavinder, the projects 
faculty advisor, may be contacted at (219) 548-7797 or christina.cavinder@valpo.edu. You may 
also contact Jennifer Winquist, Chair of the Institutional Review Board at Valparaiso Univeristy 
at (219) 464-6841 or jennifer.winquist@valpo.edu if you have questions or concerns regarding 
the conduction of the evidence-based practice project.  
 
Consent to Participate: As the child’s guardian, you have read (or someone has read to you) 
this form, and you are aware that your child is being asked to participate in an evidence-based 
practice project. You have had the opportunity to ask questions and have had them answered to 
your satisfaction. You are voluntarily agreeing for your child’s participation in this project. You 
understand the information that has been presented to you. By signing and submitting this form, 
you are agreeing to your child’s participation in this project. A copy of this form will be offered 
for your records. 
 
 
Legal Guardian Signature:          
 
Date:            
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Appendix C 
 
 
 
